Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Investor Presentation (November 2015)
24 slides from Aurobindo Pharma's investor presentation, November 2015
Slide 1: Investor Presentation November 2015
INVESTOR PRESENTATION November 2015
Slide 2: Disclaimer
Disclaimer This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these
Slide 3: Global Pharmaceutical Industry
Global Pharmaceutical Industry Global spending on prescription medicines grew by approximately US$194 billion between 2008 and 2013, and is expected to reach size of c.US$1.3 trillion in 2018 Geographic Distribution of Medical Spending Contribution to Growth 2013 2018 2013-18 $1,280bn $305bn $989bn
Slide 4: Company Overview
Company Overview Net Operating Income (INR Mn) Among the Top-5 listed pharmaceutical companies from India by sales(1) and market capitalisation(2) A global company with more than 85% of operating income coming from international operations, spanning across 150+ countries Strategic advantage via vert
Slide 5: The Journey So Far…
The Journey So Far… Creation of a leading vertically integrated platform Acquired formulations Commencement of export First approval of Controlled Acquired Western European facility in USA and of APIs Substance formulations in commercial operations from Actavis Pharmacin in Netherlands Ini
Slide 6: Key Business Segments
Key Business Segments Formulations APIs US EU ARV and RoW Portfolio of 382 ANDA Focus markets ARV – Institutional Strategically filings including 214 are France, Focus on selective important business approved ANDAs Germany, participation in global – also serves as Netherlands, tenders capt
Slide 7: US Generics
US Generics AuroLife Pharma Aurobindo USA AuroMedics AuroHealth Natrol Manufacturing / Oral Rx Injectables Pharma OTC Nutraceuticals R&D Cumulative ANDA Filings and Approvals* Gross Sales (INR Mn) Broad product portfolio mix Unit wise ANDA Filings as at 30-Sept-2015 Filed Approved Under Review com
Slide 8: EU Generics
EU Generics United France Germany Netherlands Spain Italy Portugal Kingdom Gross Sales (INR Mn) One of the leading Indian companies with strong generics footprint in Europe. Presence in Rx, TGx, BGx, Hx and OTC Foray into EU markets via acquisition of and integrating commercial operations of Mil
Slide 9: ARV TGx and RoW Generics
ARV TGx and RoW Generics ARV-Overview Gross Sales (INR Mn) Globally 35 million people are HIV+ infected with only 12 million receiving treatment Focus on selective participation in global tenders (PEPFAR, Clinton Foundation / WHO, Country specific); currently caters to 2.2 million HIV+ patients
Slide 10: The Base Business : API
The Base Business : API Non-sterile Non-sterile Non-sterile Non-sterile Non- Sterile APIs Peptides SSP Cephalosporin Penem Betalactam Gross Sales (INR Mn) Amongst the most vertically integrated generic pharma platforms with API integration for c.85% of its products; offers cost competitiveness and
Slide 11: Harnessing Synergies from Acquisitions of Actavis and Natrol
Harnessing Synergies from Acquisitions of Actavis and Natrol Acquired Platform Aurobindo Contribution / Opportunity to Leverage ► Acquired commercial Infrastructure in 7 ► Achieve critical mass in several key markets in Europe countries in Apr-2014 Actavis’s ► Leveraging its vertically integrated pl
Slide 12: Consolidated Financial Performance
Consolidated Financial Performance Q2 Q2 Q1 H1 H1 Value INR Mn FY14-15 FY13-14 FY15-16 FY14-15 FY15-16 FY15-16 FY14-15 Formulations 26,806 22,365 26,371 53,177 45,115 95,586 53,785 API 6,911 6,850 7,230 14,141 13,553 27,062 28,640 Formulations % of sales 79.5% 76.6% 78.5% 78.9% 76.9% 78% 65% Net Sal
Slide 13: Debt Profile
Debt Profile Fx Loan US$ Mn Outstanding As on… 31-Mar 31-Mar 30-June 30-Sept (INR Mn) 2014 2015 2015 2015 739 741 Closing Rate1 US$ = 59.915 62.500 63.645 65.5875 609 691 INR Fx Loan restated in INR 36,512 43,173 47,189 48,508 Rupee Loan 534 876 601 858 Sales Tax Deferment 645 549 551 550 Gross Debt
Slide 14: New Business and Technology Initiatives to Support Growth
New Business and Technology Initiatives to Support Growth Peptides Enzyme ► Manufacturing peptides from short to long chain peptide ► Develops biocatalysts with applications in the pharma molecules supporting mg to kg scale sector ► Experienced team of scientists developing chemical ► Provides chemi
Slide 15: Key Investments and Expansion Plans in Place
Key Investments and Expansion Plans in Place Brownfield Expansions Greenfield Projects ► New dedicated block for lypholized vials at Unit IV (General ► Oral Solid finished dosage formulations facility at Naidupet Injectable facility) (SEZ) ► Commissioning of Penem injectables facility at AuroNext ►
Slide 16: Way Forward
Way Forward Market share gain for products in market and new products introductions (currently 115 ANDAs (1) Orals under review) Specialty 53 ANDA filings under review for injectables with a pipeline of Oncolytics, Peptides and Penem USA Expand penetration of existing OTC products and capability to
Slide 17: Thank You
Thank You For updates and specific queries, please visit our website www. aurobindo.com Investor Relations: Deepika Gupta Padhi Phone: +91-40-66725000/5401 +91 98486 67906 Email: [email protected] Corporate Office: Water Mark Building, Level-1, Plot No.11, Survey No. 9, Kondapur, Hitech City, Hyderab
Slide 18: Formulation Gross Sales Break-Up
Formulation Gross Sales Break-Up FY 2013-14 FY2014- 15 FY2015-16 INR Bn Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 USA 6.2 7.3 9.3 11.2 11.2 11.7 12.0 13.4 14.3 14.8 Europe 1.7 1.7 1.5 1.8 8.0 7.7 8.6 7.7 7.4 7.6 RoW 1.1 0.9 1.3 1.3 1.4 1.6 1.3 1.4 1.7 1.7 ARV 1.9 2.3 2.2 1.9 2.2 1.4 3.3 2.7 3.0 2.7 Total Formul
Slide 19: API Gross Sales Break-up
API Gross Sales Break-up FY 2013-14 FY2014-15 FY2015-16 INR Bn Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Cephalosporin 2.2 2.1 2.2 2.3 2.1 2.3 2.5 2.4 2.6 2.3 SSPs 2.2 2.4 2.6 2.5 2.4 2.2 2.1 2.0 2.2 2.0 Non-Betalactam 2.1 2.7 2.7 2.7 2.2 2.4 2.2 2.4 2.5 2.6 Total API Sales 6.5 7.2 7.4 7.5 6.7 6.9 6.7 6.8 7.2 6
Slide 20: Filing details as on 30th Sept 2015
Filing details as on 30th Sept 2015 As at As at As at Apr’15- Jul’ 15- As at Category Approvals Mar 13 Mar 14 Mar 15 Jun’15 Sept’15 Sept’15 Formulations Advanced Markets 214 (FA: 186 TA: 28) (net US FDA^ 269 336 376 3 3 382 of withdrawals) 1235 dossiers (133 Europe* 1,341 1,542 1,756 47 242 2,045 pr
Slide 21: Extensive Manufacturing Base with High Quality Control and Compliance
Extensive Manufacturing Base with High Quality Control and Compliance Finished Dose Formulations Active Pharma Ingredients Site Product Capabilities Site Product Capabilities Unit III Non antibiotics, ARVs / orals Unit I CVS, CNS, Anti-Allergics, Non-Sterile Unit IV Injectables (Non-antibiotics) Uni
Slide 22: 5 Year Financial Snapshot
5 Year Financial Snapshot Value INR Bn FY2011 FY2012 FY2013 FY2014 FY2015 Net sales 41.3 45.7 57.8 80.8 121.1 Dossier Income 2.5 0.6 0.8 0.2 0.1 Net Operating Income 43.8 46.3 58.6 81.0 121.2 Gross margin % of operating income 50.4% 45.5% 48.9% 55.5% 54.6% EBITDA (before Fx and other income) % to Op
Slide 23: Key Financial Indicators
Key Financial Indicators Q2 Q2 Q1 FY14- FY13- US$ Mn FY14-15 15 14 FY15-16 FY15-16 Debt As on 31-Mar- 31-Mar- 30-June- 30-Sept- (US$ Mn) 14 15 15 15 Average $ = INR 64.82 60.47 63.29 61.04 60.28 Closing 1 US Gx 228 194 226 792 564 59.92 62.50 63.65 65.59 US$ = INR EU Gx 118 127 117 523 111 Term Loan
Slide 24: Shareholding Pattern
Shareholding Pattern As on As on As on As on Group 31.03.13 31.03.14 31.03.15 30.09.15 Non-Promoter Holding 46.1% Promoter Group 54.9% 54.6% 54.0% 53.9% FII 16.8% 23.7% 29.6% 28.9% MF / Insurance 13.4% 9.8% 6.2% 6.0% Other Bodies Corporates 5.5% 2.2% 1.6% 2.3% Retail Investors 9.4% 9.7% 8.6% 9.0% To
Aurobindo Pharma — Investor Presentation (November 2015) on 6ix